VGXI Gears To Support Production Of New Coronavirus Vaccine
Initial Manufacturing Of Inovio/Advaccine Candidate
Executive Summary
VGXI, a contract manufacturer of plasmid DNA and US subsidiary of Korea’s GeneOne Life Science, joins in the R&D efforts for a DNA vaccine against the new Wuhan coronavirus, using its proprietary manufacturing platform as part of a new agreement with Inovio.
You may also be interested in...
GSK Joins Race To Tackle Coronavirus
The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.
Moderna, Inovio Coronavirus Vaccine Candidates Fast-Tracked By International Coalition
The Coalition for Epidemic Preparedness Innovations adds new deal with mRNA specialist Moderna for rapid development of coronavirus vaccine.
Need a specific report? 1000+ reports available
Buy Reports